Molecular Imaging of Brain Inflammation in Depressive Disorders

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-08-28

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In a number of neuropsychiatric disorders such as depression, both brain inflammation and glutamate mediated excitotoxicity (cell death through over-activated stimulation) are suspected to play a key role. It is difficult, if not impossible, to determine the potential destructiveness of the inflammatory response seen in disease states by studying the brain's inflammatory cells (microglia) activity in isolation. The investigators are proposing to develop the means to concurrently study inflammatory response (i.e., microglial activity) and its potentially devastating consequence (i.e., glutamate excitotoxicity) across the entire brain in order to establish the importance of inflammation. In this study the investigators propose a phased clinical study whereby the early-phase involves the development of our capacity to study inflammation-mediated damage to brain cells, followed by a feasibility study in patients with clinical depression that tests whether concurrent inflammation and glutamate excess could be measured in key brain regions associated with a depressed mood state.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Neuroimaging Study for Decoding Emotional States and Identifying Neural Circuits to Disengage From Negative Thinking

NCT06254144

Depressive Disorder, Major

ENROLLING_BY_INVITATION

Brain Imaging of Cognition Inn Schizophrenia and Depression

NCT04159662

Schizophrenia / Schizoaffective Disorder Depression / Major Depressive Disorder

RECRUITING

Neuroimaging Sleep and Mood in Depression

NCT05497414

Major Depression

UNKNOWN NA

PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX

NCT02230592

Anxiety Disorder Major Depressive Disorder

COMPLETED

Using Functional MRI Neurofeedback to Modulate Self-blame in Major Depressive Disorder

NCT05455827

Depression

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depressive Disorder, Major Positron-Emission Tomography

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PET/MRI using 18[F]EPPA ligand

given experimental ligand FEPPA during MRI/PET scan to identify glutamate activity in the brain using FEPPA ligand

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* screening form for MRI/PET is satisfactory after being reviewed by a radiologist
* diagnosed with depression or healthy control participants with no present mental health disorder
* Good general health with no diseases expected to interfere with the study
* Subject is not pregnant, lactating, or of childbearing potential (must be practicing effective form of birth control)
* Patient and healthy controls must not have an infection or an autoimmune disorder or persistent inflammation.

Exclusion Criteria

* Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol
* use of Investigational agents within last month

Minimum Eligible Age

19 Years

Maximum Eligible Age

105 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes